glp-1 bulk list exclusion

FDA to exclude semaglutide, tirzepatide and liraglutide on 503B bulks list — Photo by www.kaboompics.com on Pexels

Can Pharmacies Safely Use Semaglutide after FDA Exclusion?

Can Pharmacies Safely Use Semaglutide after FDA Exclusion? 90% of patients who obtain semaglutide through compounding pharmacies will face new sourcing rules, and the drug can still be dispensed safely only if pharmacies shift to the branded product or a compliant 503B source. The FDA exclusion removes bulk-list compounding but